Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) today announced that it has commenced an underwritten public offering of 4,500,000 shares of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE